UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049064 |
|---|---|
| Receipt number | R000055897 |
| Scientific Title | Effects of consumption of the test food on urination-related quality of life: a randomized, placebo-controlled, double-blind, parallel-group comparison study |
| Date of disclosure of the study information | 2023/09/28 |
| Last modified on | 2023/10/11 09:22:28 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects on urination-related quality of life
Acronym
Effects on urination-related quality of life
Scientific Title
Effects of consumption of the test food on urination-related quality of life: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Scientific Title:Acronym
Effects of consumption of the test food on urination-related quality of life
Region
| Japan |
Condition
Condition
Healthy Japanese subjects
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the effects of consumption of the test food on urination-related quality of life
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
1. The overactive bladder questionnaire (OAB-q)
Key secondary outcomes
1. The Pittsburgh Sleep Quality Index (PSQI), the Core Lower Urinary Tract Symptom Score (CLSS), and the Nocturia Quality of Life questionnaire (N-QOL)
2. 8-hydroxy-2'-deoxyguanosine (8-OHdG) level in the urine and the blood levels of diacron-reactive oxygen metabolites (d-ROM), biological anti-oxidant potential (BAP), dihydrotestosterone (DHT), testosterone, lipid hydroperoxide (LPO), and blood pressure
3. The average frequency of urination in the daytime, in the nighttime, and during the day, and the urination amount on rising
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
Institution consideration
Institution is not considered as adjustment factor.
Blocking
YES
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Duration: Eight weeks
Take one active food with water before breakfast once daily
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
Interventions/Control_2
Duration: Eight weeks
Take one placebo food with water before breakfast once daily
*If you forget to take the test food, take it as soon as you remember. Daily dose should be taken within the day and not carried over to the next day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 64 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1. Japanese
2. Men or women
3. Subjects aged between 40 and 64
4. Healthy subjects
5. Subjects whose frequency of urination is eight or more in the daytime
6. Subjects whose frequency of urination is two or more in the nighttime
7. Subjects whose score of urinary urgency of the Overactive Bladder Symptom Score (OABSS) is less than two or total score of OABSS is less than three at screening (before consumption: Scr)
8. Subjects whose total score of OABSS is five or less at Scr
9. Subjects whose score of the International Prostate Symptom Score (IPSS) is seven or less
Key exclusion criteria
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Subjects who are currently undergoing treatment for any of the following chronic diseases:
urination disorder, sleep disorder, cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or particularly urination-related health food on a daily basis
5. Subjects who drink to excess (average of more than about 20 g/day as absolute alcohol intake) {500 mL: a medium bottle of beer or about 1.5 cans of canned chu-hi, 180 mL: 1 go of sake or about 1.5 glasses of wine, 90 mL: half-go with shochu, 60 mL: a glass of whiskey brandy (double)}
6. Subjects whose sleeping time or habit is irregular due to work such as a late-night shift
7. Subjects whose sleeping and waking time are irregular and whose sleeping hours is five or less
8. Subjects who sleep with more than one person
9. Subjects who take health food or nutritional supplement with anti-oxidative capacity
10. Subjects who are currently taking medications (including herbal medicines) and supplements
11. Subjects who are allergic to medicines and/or the test food related products
12. Subjects who are pregnant, lactating, or planning to become pregnant during this trial
13. Subjects who suffer from COVID-19
14. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
15. Subjects who are judged as ineligible to participate in this study by the physician
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Organization
Medical Corporation Seishinkai, Takara Clinic
Division name
Director
Zip code
141-0022
Address
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
TEL
03-5793-3623
t-takara@takara-clinic.com
Public contact
Name of contact person
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
ORTHOMEDICO Inc.
Institute
Department
Personal name
Funding Source
Organization
Hayashikane Sangyo Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic
Name of secondary funder(s)
IRB Contact (For public release)
Organization
the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
Tel
03-5793-3623
IRB@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 09 | Month | 28 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
56
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2022 | Year | 09 | Month | 14 | Day |
Date of IRB
| 2022 | Year | 09 | Month | 14 | Day |
Anticipated trial start date
| 2022 | Year | 09 | Month | 29 | Day |
Last follow-up date
| 2023 | Year | 02 | Month | 19 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2022 | Year | 09 | Month | 29 | Day |
Last modified on
| 2023 | Year | 10 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055897
